extended

The Difference in Guanfacine Formulations for ADHD

By: Katharine Cimmino, Editor-in-Chief - Attention-deficit/hyperactivity disorder (ADHD) is the most common pediatric psychiatric disorder, and it affects the education,…

12 years ago

Antipsychotic Use in the Elderly with Dementia

By: Ada Seldin, Staff Editor - The overuse of antipsychotics in the nursing home population for off-label indications continues to…

12 years ago

Nattokinase use in DVT prophylaxis

Samad Tirmizi, Pharm. D. Candidate c/o 2014 - Deep vein thrombosis (DVT) is a clot formation that occurs within deep…

13 years ago

New Findings Regarding Cardiovascular Adverse Events with ADHD Medications

By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] - Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns…

13 years ago

Two New Agents for the Treatment of Obesity

By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU - Obesity is defined as having a body mass index…

13 years ago

FDA Takes Major Strides Towards Opioid Abuse Prevention

By: Ada Seldin PharmD Candidate c/o 2015 - On April 16th, 2013, the FDA approved the labeling change for the…

13 years ago

Pay to Delay: The Honest Truth

By: David Ong, Pharm.D. Candidate c/o 2014 - Our current healthcare system receives much criticism from the press as well…

13 years ago

Can a Pharmacist Prevent the Next Pileup?

By: Moisey Rafailov, PharmD Candidate c/o 2015 - It was early in the morning on New York’s Route 684 when…

13 years ago

Safety and Efficacy of Atropine for Salivary Hypersecretion

By: Elsa Thomas, PharmD Candidate c/o 2013 - Atropine is an anticholinergic used to treat various conditions, such as bradycardia,…

14 years ago

Meet the new Beta 3 Agonist: Mirabegron (Myrbetriq®)

By: Steve P. Soman - Mirabegron (Mybetriq®), known also by the brand name Betanis®in Japan, is a new once daily…

14 years ago

Artificial Saliva Agents in Xerostomia

By: Neal Shah, Co-Editor-in-Chief - Xerostomia, commonly known as dry mouth, is an anti-muscarinic side effect of numerous medications.  Antidepressants,…

14 years ago

A Reflection of my Palliative Care Rotation

By: Stanley Saji, Pharm.D. Candidate c/o 2013 - I had a preconceived notion that advanced pharmacy practice experiences (APPEs) were…

14 years ago

Proton Pump Inhibitor Use and Complications

By: Lauren Kaveski, Pharm.D. Candidate c/o 2013 - We see proton pump inhibitors (PPIs) used in many medication regimens, but…

14 years ago

My Residency, My Experience, A Foundation for My Career

By: Sum Lam, PharmD, CGP, BCPS, FASCP - Sum Lam, Pharm.D., CGP, BCPS, FASCP is an Associate Clinical Professor in…

14 years ago

The Importance of Researching Residency Sites

By: Dr. Regina Ginzburg - Regina Ginzburg is an Associate Clinical Professor of St. John’s University College of Pharmacy and…

14 years ago

Bydureon®: A Weekly Injection for Type 2 Diabetes Mellitus

By: Mohamed Dungersi - On January 27, the FDA approved Bydureon® (exenatide extended-release) for use in Type 2 Diabetes Mellitus…

14 years ago